A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the ...

There’s been an exciting new development for some patients with metastatic colorectal cancer: a groundbreaking FDA approval has introduced a new treatment option specifically designed for those with ...

Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Clinical Utility of Molecular Tumor Board Review for Identification of Possible Germline Pathogenic Variants on Tumor Next-Generation Sequencing Reports We demonstrate dynamic evolution of resistance ...

CHICAGO -- First-line treatment with encorafenib (Braftovi) and cetuximab (Erbitux) plus chemotherapy significantly improved survival outcomes compared with standard of care in patients with BRAF ...

LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...

A post hoc analysis of the PETACC-8 trial has revealed an interaction between microsatellite instability (MSI) and BRAF and KRAS mutation status when determining the prognosis of patients with ...

Researchers from Japan report that they have characterized gene mutations in colorectal cancer (CRC) tumors with high tumor mutation burden that lack mutations in the major oncogenes. Their findings ...

Phase III trial results supported recent FDA approval for patients with BRAF V600E mutations Data from this multi-institutional collaboration across 28 countries supported the accelerated approval of ...